Authors: Iskedjian, Michael¹; Walker, John H.; Gaston De Serres,²; Einarson, Thomas R.

Source: Pediatric Drugs, Volume 7, Number 2, 2005 , pp. 123-136(14)

Publisher: Adis International

Abstract:

Objective: Pertussis is a frequent cause of cough illness in adolescents. In Canada, immunization against pertussis in public programs has been restricted to children under 7 years of age. The purpose of this analysis was to estimate the health and economic impact of an additional booster dose of the acellular vaccine in adolescents in Québec.

Method: We performed a cost-effectiveness analysis, based on a predictive spreadsheet dynamic model following a cohort of 90 929 adolescents in Québec from the age of 14 years over a 10-year period from the Québec Ministry of Health (MOH) and societal (SOC) perspectives. The model was used to compare costs (2003 values) and benefits of an adolescent vaccination program (AVP), including a diptheria, tetanus, and acellular pertussis (dTacp) vaccine administered at age 14 years, with current practice.

Results: From the MOH perspective, a booster vaccination of dTacp at age 14 years via the AVP would produce a yearly additional expected cost of $Can1.06 per adolescent with an incremental cost-effectiveness ratio (ICER) of $Can480 per pertussis case avoided based on a 10-year period. When outcomes are discounted at 3%, the ICER rises to $Can527 per discounted pertussis case avoided. From the SOC perspective, the AVP would cost $Can0.83 per adolescent per year with an additional cost per avoided pertussis case of $Can377 ($Can414 per additional discounted case of pertussis avoided). Over the 10-year period, 2012 non-discounted cases of pertussis would be prevented with approximately two hospital admissions averted.

Conclusion: This study suggests that administering a booster dose of dTacp at age 14 years to replace the diptheria and tetanus vaccination will slightly increase the economic burden from MOH and SOC perspectives; however, the number of pertussis cases and the number of hospital admissions will decrease.

Keywords: Adolescents; Pharmacoeconomics; Pertussis; Pertussis acellular vaccine

Document Type: Research article

Affiliations: 1: 1 PharmIdeas Research and Consulting Inc., Oakville, Ontario, Canada 2: 3 Infectious Diseases Unit, Centre de Santé Publique de Québec, Québec City, Québec, Canada

Publication date: 2005-01-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pediatrics ,  Pharmacology
• By this author: Iskedjian, Michael ;  Walker, John H. ;  Gaston De Serres, ;  Einarson, Thomas R.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers